VolitionRx Limited (NYSEMKT:VNRX) Files An 8-K Results of Operations and Financial Condition
Item2.02.
Results of Operations and Financial Condition.
The following information, including Exhibits 99.1 and 99.2, is
being furnished in accordance with General Instruction B.2. of
Form 8-K and shall not be deemed filed for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the Exchange
Act), or otherwise subject to the liabilities of that section,
nor shall it be deemed to be incorporated by reference in any
filing under the Securities Act of 1933, as amended (the
Securities Act), or the Exchange Act, except as expressly set
forth by specific reference in such filing:
As previously announced, on November 10, 2016, VolitionRx Limited
hosted a conference call discussing its financial results for the
quarter ended September 30, 2016. The conference call was
announced by a widely disseminated press release and was made
available to the public via audio webcast. Furnished herewith as
Exhibits 99.1 and 99.2 and incorporated by reference herein are
copies of the press release and a transcript of the conference
call, respectively.
Item 9.01.
Financial Statements and Exhibits.
(d)
Exhibits.
|
Exhibit Number |
Description |
|
99.1 |
Press Release of VolitionRx Limited, dated November 10, |
|
99.2 |
Transcript of Conference Call held on November 10, 2016. |
About VolitionRx Limited (NYSEMKT:VNRX)
VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease. The Company’s Nucleosomics biomarker platform is a technology that is used for a range of cancers. The Company is developing Nucleosomics tests for various cancers, including colorectal, pancreatic, lung and aggressive prostate. The Company’s NuQ blood assays fall into over five types, which include NuQ-X, NuQ-V, NuQ-M, NuQ-A and NuQ-T. It has developed approximately two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides. VolitionRx Limited (NYSEMKT:VNRX) Recent Trading Information
VolitionRx Limited (NYSEMKT:VNRX) closed its last trading session 00.00 at 4.12 with – shares trading hands.
